Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Trade House Allergen is a specialized Russian pharmaceutical company focused on the distribution and supply of immunobiological products, particularly in the field of allergology and immunology. The company serves as a primary commercial link for allergen extracts used in both diagnostic skin testing and allergen-specific immunotherapy (ASIT) for conditions such as pollinosis and asthma. Beyond its core allergy portfolio, Trade House Allergen distributes a variety of vaccines, toxoids, and diagnostic reagents, including tuberculin for tuberculosis screening. The firm maintains strategic partnerships with major domestic manufacturers, most notably the Stavropol-based Allergen production facility under NPO Microgen. By managing a complex cold-chain logistics network, the company ensures the delivery of temperature-sensitive biologics to medical institutions across Russia and the CIS region. Trade House Allergen plays a critical role in the Russian healthcare market by providing essential tools for the management of allergic and infectious diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Trade House Allergen.